Bristol Myers Squibb (“BMS”), one of the world’s leading oncology companies, has entered into a license agreement with Housey Pharma to license its core enabling technologies for new drug discovery directed toward difficult and “undruggable” targets in the human genome. This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies are lacking.
“We are pleased to share this core technology with our scientific colleagues at Bristol Myers Squibb. We are excited by the use of these technologies throughout the industry in the in search for new medicines that will benefit people around the world,” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma.
